This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Charles E. Thirkill, PhD; John L. Keltner, MD; Nancy K. Tyler, PhD; Alan M. Roth, MD

Arch Ophthalmol. 1993;111(7):931-937.

Abstract
Objective
Our objectives were to determine what clinical characteristics are common to the form of cancer-associated retinopathy (CAR) encountered in patients with small-cell carcinoma of the lung (SCCL). Is the 23-kd retinal CAR antigen/antibody reaction present in other forms of retinopathy? Can an antigen identical or similar to the 23-kd retinal CAR antigen be identified in an established culture of SCCL?

Methods
Ten patients with CAR who had SCCL were identified by their antibody reactivity with the 23-kd retinal CAR antigen. We inquired into common clinical characteristics by means of questionnaires to the referring physicians. We looked for antigen/antibody reactions with the 23-kd retinal CAR antigen in patients with diabetic and age-related macular degenerations and in a continuous, in vitro propagated culture of SCCL (HTB 119) obtained from the American Type Culture Collection.

Results
We encountered many similar signs and symptoms in our patient population. These included rapid vision loss, night blindness, color loss, vitreous cells, and either flat or greatly reduced electroretinograms. No corollary to the 23-kd CAR antigen/antibody could be identified in unrelated retinopathies or cultured SCCL.

Conclusions
We conclude that patients with SCCL related CAR consistently produce antibodies against the 23-kd retinal CAR antigen. This immunologic reaction was not found in patients with unrelated retinopathies and may possibly represent a cancer marker for SCCL.

Author Affiliations
From the University California, Davis, Medical Center, Eye Research, Sacramento. Dr Thirkill is a consultant to Genica Pharmaceuticals. The other authors do not have a proprietary interest in the materials mentioned in this study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retinal Dysfunction in Cancer-Associated Retinopathy Is Improved by Ca2+ Antagonist Administration and Dark Adaptation
Ohguro et al.
IOVS 2001;42:2589-2595.
ABSTRACT | FULL TEXT  

Distant cancer effects on standardised testing of peripheral vision
Dawson et al.
Br J Ophthalmol 2001;85:291-296.
ABSTRACT | FULL TEXT  

Autoimmune Retinopathy: Patients With Antirecoverin Immunoreactivity and Panretinal Degeneration
Heckenlively et al.
Arch Ophthalmol 2000;118:1525-1533.
ABSTRACT | FULL TEXT  

Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer
Gure et al.
Proc. Natl. Acad. Sci. USA 2000;97:4198-4203.
ABSTRACT | FULL TEXT  

Aberrant Expression of Photoreceptor-specific Calcium-binding Protein (Recoverin) in Cancer Cell Lines
Maeda et al.
Cancer Res. 2000;60:1914-1920.
ABSTRACT | FULL TEXT  

Cancer-Associated Retinopathy Induced by Both Anti-Recoverin and Anti-hsc70 Antibodies In Vivo
Ohguro et al.
IOVS 1999;40:3160-3167.
ABSTRACT | FULL TEXT  

Cancer-Associated Retinopathy
Goldstein et al.
Arch Ophthalmol 1999;117:1641-1645.
ABSTRACT | FULL TEXT